Early and mid-term results after endovascular repair of thoracoabdominal aortic aneurysms using the off-the-shelf multibranched t-Branch device: a national multi-center study.

Objective: The multibranched off-the-shelf Zenith® t-Branch (Cook Medical, Bloomington, IN) device is commonly chosen for endovascular repair of thoracoabdominal aortic aneurysms. The aim of this study was to report early and mid-term outcomes in all patients treated with the t-Branch in Norway; Design and Methods: A retrospective multicenter study with Norwegian centers performing complex endovascular aortic repair was undertaken. T-Branch patients from 2014 to 2020 were included. All postoperative computed tomography angiography images were reviewed, and demographic, anatomical, perioperative and follow-up data were analyzed; Results: Seventy patients were treated in a single-step (n = 55) or staged (n = 15) procedure. Symptomatic presentation was seen in 20 patients, six of which had a contained rupture. Technical success was 87% (n = 59), with failures caused by unsuccessful bridging of target vessels (n = 4), target vessel bleeding (n = 3), persisting type 1c endoleak (n = 1) and t-Branch malrotation (n = 1). 30-day mortality was 9% (n = 6) and was associated with high BMI (p = .038). The spinal cord ischemia rate was 21% (n = 15) and was associated with type II aneurysms (OR 5.4, 95% CI 1.1-26.7, p = .04), smoking (OR 6.0, 95% CI 1.3-27.6, p = .02) and intraoperative blood loss (OR 1.1, 95% CI 1.0-1.3, p = .01). Survival at one, two and three years was 84 ± 4%, 70 ± 6% and 67 ± 6%, respectively. Freedom from aortic-related reinterventions at one, two and three years was 80 ± 5%, 65 ± 7% and 50 ± 8%, respectively; Conclusion: The study showed low early mortality (9%) and satisfactory mid-term survival. Technical success was achieved in acceptable 87% of procedures. The rate of spinal cord ischemia was high, occurring in 21% of patients.

This paper provides a national experience of all TAAA patients treated with the multibranched t-Branch stent graft in Norway in a multi-center study. As we aimed at including all Norwegian patients operated with the device, the paper adds real-world data on t-Branch outcomes from four regional smaller-volume vascular centers.The paper provides technical and clinical mid-term results with several patients being followed up for >3 years.Technical success was achieved in 87% of procedures.The 30-day mortality rate was 9% and survival at one, two and three years was 85 ± 4%, 70 ± 6% and 67 ± 6%, respectively.Spinal cord ischemia was associated with Crawford type II aneurysms, smoking and intraoperative blood loss.

Three-dimensional ultrasound volume and conventional ultrasound diameter changes are equally good markers of endoleak in follow-up after endovascular aneurysm repair.

INTRODUCTION: The main disadvantages of computed tomography angiography (CTA) in follow-up after endovascular aneurysm repair are the risks of contrast-induced renal impairment and radiation-induced cancer. Three-dimensional ultrasound is a new technique for volume estimation of the aneurysm sac. Some studies have reported promising results. The aim of this study was to evaluate the accuracy and precision of three-dimensional ultrasound aneurysm sac-volume estimates, and to explore whether volume and/or diameter changes on ultrasound can be used as markers of endoleak. METHODS: A single-center diagnostic accuracy study was performed. A total of 92 patients planned for endovascular aneurysm repair were prospectively and consecutively enrolled (2013-2016). Aneurysm sac diameter and volume were measured using CTA, conventional ultrasound, and three-dimensional ultrasound preoperatively and 1, 6, 12, and 24 months postoperatively. Three-dimensional ultrasound was performed with a commercially available electromechanical transducer. Patients with endoleak were observed 5 years after endovascular aneurysm repair. RESULTS: A total of 79 men and 13 women were included. Mean age was 74 years (57-92 years). Median follow-up was 24 months. Endoleak cases were observed for up to 55 months. Diameter measurements on conventional ultrasound correlated well with CT diameters (r = 0.9, P < .05, n = 347), and Bland-Altman analyses showed an upper limit of agreement of +0.5 cm and a lower limit of agreement of -0.8 cm. The mean difference was -0.13 cm ± 0.36 cm. Three-dimensional ultrasound volumes had a correlation with CTA diameters of r = 0.8 (P < .05, n = 347) and with three-dimensional CT volumes of r = 0.8 (P < .05, n = 155). Receiver operating characteristic analyses showed that the diameter and volume changes that led to reintervention were most accurate at 24-month follow-up, with area-under-the-curve percentage changes of 0.98 (two-dimensional ultrasound), 0.97 (three-dimensional ultrasound), and 0.97 (two-dimensional CT). DISCUSSION: Both diameter and volume changes can be used as markers for endoleak with excellent areas under the curve on receiver operating characteristic analyses. However, three-dimensional ultrasound volumes did not add any further diagnostic information. Conventional 2D diameter measurements were as accurate as volume changes as markers of endoleak. CONCLUSIONS: Type II endoleaks can safely be followed up using a simple diameter measurement on conventional ultrasound.

Contrast-enhanced ultrasound detects type II endoleaks during follow-up for endovascular aneurysm repair.

OBJECTIVE: Repeated computed tomography angiography (CTA) can be used during follow-up visits for endovascular aneurysm repair (EVAR) but leads to accumulated radiation exposure and may cause renal impairment. Therefore, the use of contrast-enhanced ultrasound (CEUS) has increased, and its ability to detect endoleaks has been promising. The aim of this study was to investigate the diagnostic accuracy of CEUS vs CTA for endoleak detection during EVAR follow-up. METHODS: Ninety-two patients with planned EVAR for abdominal aortic aneurysm were prospectively, consecutively enrolled. In total, 233 paired CTA and CEUS procedures were performed within the same day. Follow-up visits occurred 1 month, 6 months, 12 months, and 24 months postoperatively. RESULTS: Of 48 endoleaks discovered by CTA, 39 were also detected on CEUS, giving an overall sensitivity of 81.3% and specificity of 98.9%. All undetected endoleaks were minor, without clinical importance, and occurred in patients with high body mass index. CONCLUSIONS: In this study, CEUS was accurate for detecting type II endoleaks during follow-up visits for EVAR. Sensitivity was lower in obese patients. Doppler ultrasound has low sensitivity and seems to be unsuitable for the detection of endoleaks.

Pseudoaneurysm of the abdominal aorta due to a needle-like osteophyte on the first lumbar vertebra.

A 46-year-old woman was admitted with acute abdominal pain radiating to the back. Computed tomography examinations showed a needle-thin perforation of the aorta, opposite the origin of the superior mesenteric artery, with a pseudoaneurysm. A needle-sharp spinal osteophyte was located exactly opposite the perforation. There was no sign of infection, and the perforation seemed to have been caused by the osteophyte. This aortic perforation occurred without any major trauma, but repeated minor occupational trauma to her abdomen may have played an etiologic role. The pseudoaneurysm and adjacent aorta were exposed through a thoracolaparotomy. The aortic wall was normal, with good tensile strength; therefore, the perforation in the aortic wall was sutured with a double vascular suture, and the osteophyte was resected. To our knowledge, aortic perforation due to a vertebral osteophyte in the absence of major trauma has not previously been described.

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

The polycomb group protein enhancer of zeste homologue 2 (EZH2) has been linked to invasive properties of aggressive breast cancer. In this report, tissue microarray analysis of 190 breast carcinomas from a nested case-control study shows that EZH2 is significantly associated with interval breast cancers. Further, a strong relationship was found with tumor cell proliferation (by Ki-67 expression), locally advanced disease, metastasis at presentation, markers of the basal epithelial phenotype (positivity for cytokeratin 5/6 or P-cadherin), and p53 status. EZH2 expression was also significantly associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype. For prediction of aggressive disease (any event of locally advanced disease, lymph node spread, or distant spread), EZH2 was the only variable of significance in multivariate analysis, whereas no additional information was given by Ki-67. Although EZH2 expression was significant in univariate survival analysis, only tumor cell proliferation and lymph node status were significant in the final multivariate model. In conclusion, our findings indicate an important relationship not only between EZH2 and markers of tumor cell proliferation but also with aggressive disease. These findings might be practically important and relevant because the polycomb group proteins have recently been suggested as candidates for targeted therapy.

Influence of review design on percentages of missed interval breast cancers: retrospective study of interval cancers in a population-based screening program.

PURPOSE: To retrospectively investigate whether different review designs have an influence on the estimate of missed interval cancer in a population-based breast cancer screening program. MATERIALS AND METHODS: The Norwegian Breast Cancer Screening Program invites women aged 50-69 years to undergo biennial screening mammography. The current study was part of the evaluation and scientific aspects of the screening program and thus was covered by the general ethical approval of the screening program as a part of the Cancer Registry of Norway. All participants signed an informed consent that specified that data related to their screening visit could be used for evaluation and scientific purposes. Six radiologists (9-34 years of experience in mammography) reviewed previously obtained bilateral two-view screening and diagnostic mammograms of 231 interval cancers, 117 screening-detected cancers, and 373 normal cases. Four review designs were used: individual and paired blinded review and individual and consensus informed review. A five-point interpretation scale was used to reclassify the cancers into missed cancers, minimal signs, and true cancers. The number and proportion of subgroups were estimated with 95% confidence intervals. RESULTS: Of 231 interval cancers, 46 (19.9%) were reclassified as missed cancers with the mixed blinded individual review and 54 (23.4%) were classified as missed cancers with the mixed blinded paired review. Eighty-three cancers (35.9%) were classified as missed cancers with individual informed review, and 78 (33.8%) were classified as missed cancers with consensus informed review. Thirty-nine cancers (16.8%) were reclassified as missed when four or more radiologists assigned a score of 2 or more (probably benign or more suspicious); three cancers (1.3%) were reclassified as missed when a score of 4 or more (probably malignant or more suspicious) was assigned. CONCLUSION: The percentage of interval cancers classified as missed ranged from 1.3% to 35.9% according to review design. To encourage learning, a review protocol should include both blinded and informed designs.

A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.

Interval breast cancer reduce the effectiveness of mammography screening programs. We studied 95 interval cancers, diagnosed during 1996 to 2001 as part of the population-based Norwegian Breast Cancer Screening Program. These cases were matched on size (+/-2.0 mm) to 95 screen-detected breast cancers, and the tumors were compared by immunohistochemical methods using tissue microarrays. Patients with interval cancers were more likely to be younger [odds ratio (OR), 4.7; P = 0.0001], to have dense breasts (OR, 3.4; P = 0.004), and to have estrogen receptor-negative tumors (OR, 2.6, P = 0.01), and p53 expression was more frequent (OR, 4.0; P = 0.001). Notably, interval cancers were more likely to have a basal epithelial phenotype, in that expression of cytokeratin 5/6 (OR, 2.3; P = 0.04) and P-cadherin (OR, 2.5; P = 0.04) was more frequent in interval cases than in size-matched, screen-detected tumors. In a logistic regression model, p53 expression, age, and breast density were independent predictors of interval cancers. Our data suggest that breast cancers with a basal epithelial phenotype are more likely than nonbasal breast cancers to present between regular mammograms.